US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
SHANGHAI, April 2 (Bernama-AsiaNet) — On March 31, 2021, Jemincare Group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed…